A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Recruitment Status
ACTIVE, NOT RECRUITING - HAS RESULTS
(See Contacts and Locations)Verified September 2025 by Eli Lilly and Company
Sponsor
Eli Lilly and Company
Information Provided by (Responsible Party)
Eli Lilly and Company
Clinicaltrials.gov Identifier
NCT05767021
Other Study ID Numbers:
18551
First Submitted
February 7, 2023
First Posted
March 13, 2023
Results First Posted
August 7, 2025
Last Update Posted
October 27, 2025
Last Verified
September 2025

ClinicalTrials.gov processed this data on October 2025Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Ulcerative ColitisUlcerative Colitis Chronic
Drug: Mirikizumab

Study Design

Study TypeInterventional
Actual Enrollment172 participants
Design AllocationN/A
Interventional ModelSingle Group Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Study Start DateMay 16, 2023
Actual Primary Completion DateAugust 8, 2024
Actual Study Completion DateMarch 31, 2026

Groups and Cohorts

Group/CohortIntervention/Treatment
300 mg Mirikizumab
Participants received 300 milligram (mg) mirikizumab every 4 weeks (Q4W) at week 0, 4, and 8 administered intravenously (IV).
Drug: Mirikizumab
Administered IV

Outcome Measures

Primary Outcome Measures
  1. Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)
    The UNRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Baseline Observation Carried Forward (BOCF) endpoint was defined as the baseline value for participants discontinued during acute phase and defined as the last non-missing observation in the treatment phase for all other randomized participants.
Secondary Outcome Measures
  1. Change From Baseline in Bowel Urgency Frequency (BUF)
    BUF is participant reported single item measure of the number of urgent bowel movements reported in the past 24 hours.
  2. Percentage of Participants Achieving Clinically Meaningful Improvement in BUF
    This outcome measures the percentage of participants who experience a clinically meaningful reduction in the frequency of bowel urgency episodes from baseline to the 12 week treatment period. Results for this outcome will be reported during final results posting.
  3. Percentage of Participants With Stool Deferral Time (SDT) Intervals at Week 12
    The SDT is a participant-reported single item measure of the average duration a patient could delay defecation in the past 24 hours. The shortest weekly SDT is used for analysis of SDT in minutes by taking the shortest response (i.e. minimum value) available over the past 7 days, where no urgency is treated as the largest value. The SDT categories were:\<1 min, ≥1 min to \<2 min, ≥2 min to \<5 min, ≥5 min to \<15 min, and ≥15 min or no urgency. No urgency indicates participant's selected "Did not feel urge to have a bowel movement in the past 24 hours" for all available days in 7-day period.
  4. Percentage of Participants Achieving Clinically Meaningful Improvement of SDT
    This outcome measures the percentage of participants who demonstrate a clinically meaningful improvement in SDT. Results for this outcome will be reported during final results posting.
  5. Percentage of Participants Achieving Both Clinical Remission, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score of ≤1
    Clinical remission based on MMS is defined as Stool Frequency (SF) sub score (range 0-3, higher is worse) = 0, or SF = 1 with a ≥1- point decrease from baseline, and 1. Rectal Bleeding (RB) sub score (range 0-3, higher is worse) = 0, and 2. Endoscopic sub score (ES) (range 0-3, higher is worse) = 0 or 1 (excluding friability). UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome assesses the proportion of participants who achieved both a clinical response, as defined by an MMS, and an improvement of ≥3 points from baseline in a UNRS score at Week 12.
  6. Percentage of Participants Achieving Both Clinical Response, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score ≥3 Points of Improvement From Baseline
    Clinical response based on MMS is defined as: 1. A change in the MMS of ≤ -2 points and ≤ -30% change from baseline, and 2. A change of ≤-1 point in the RB subscore (range 0-3, higher is worse) from baseline or a RB score of 0 or 1. UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome measures the percentage of participants achieving both, clinical response, based on the MMS, and a UNRS score of ≥3 points of improvement from baseline at 12 weeks.
  7. Pairwise Correlations Between the Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures
    UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations among four bowel urgency-related measures above.
  8. Pairwise Correlations Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures
    UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations between the change in correlations among four bowel urgency-related measures above.
  9. Correlation Between Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF),Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures,With Quality of Life (QoL)/Functional Outcome Measures and UC Symptom Measures
    This outcome evaluates correlations between UNRS, BUF, SDT, APU, and patient-reported outcomes (PROs) related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem,7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7; total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)
  10. Correlation Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures, With QoL/Functional Outcome Measures and UC Symptom Measures
    This outcome evaluates correlations between change from baseline in UNRS, BUF, SDT, APU, and PROs related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem, 7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7;total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Have an established diagnosis of UC for ≥3 months
Have confirmed diagnosis of moderately for severely active UC
Have current bowel urgency
Have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic/Janus Kinase (JAK) inhibitor/sphingosine-1-phosphate (S1P) receptor modulator therapy for UC.
Exclusion Criteria
Have Crohn's disease (CD)
Have inflammatory bowel disease-unclassified, formerly known as indeterminate colitis, or
Have ulcerative proctitis, disease limited to the rectum, that is, distal to the recto-sigmoid junction, which lies approximately 10 to 15 centimeter (cm) from anal verge.
Have an inherited immunodeficiency syndrome or a monogenic cause of UC-like colonic inflammation
Have any history or current evidence of cancer of the gastrointestinal tract
Have active tuberculosis
Have HIV infection.

Contacts and Locations

Sponsors and CollaboratorsEli Lilly and Company
Locations
Dedicated Clinical Research | Litchfield Park Arizona, United States, 85340Arizona Digestive Health - Sun City | Sun City Arizona, United States, 85351Om Research, LLC | Lancaster California, United States, 93534California Medical Research Associates, Inc. | Northridge California, United States, 91324Clinical Applications Laboratories, Inc. | San Diego California, United States, 92103Medical Research Center of Connecticut, LLC | Hamden Connecticut, United States, 06518Central Florida Gastro Research | Clearwater Florida, United States, 33762Encore Borland-Groover Clinical Research | Jacksonville Florida, United States, 32256Research Associates of South Florida | Miami Florida, United States, 33134Advanced Research Associates, LLC | Miami Florida, United States, 33176GCP Clinical Research, LLC | Tampa Florida, United States, 33609International Center for Research LLC | Tampa Florida, United States, 33614Digestive Healthcare of Georgia | Atlanta Georgia, United States, 30309Atlanta Center for Gastroenterology, P.C. | Decatur Georgia, United States, 30033Grand Teton Research Group, PLLC | Idaho Falls Idaho, United States, 83404IU Health University Hospital | Indianapolis Indiana, United States, 46202Gastroenterology Health Partners | New Albany Indiana, United States, 47150Cotton-O'Neil Clinical Research Center, Digestive Health | Topeka Kansas, United States, 66606GI Alliance/ Metairie | Metairie Louisiana, United States, 70006Delta Research Partners | Monroe Louisiana, United States, 71201Chevy Chase Clinical Research | Chevy Chase Maryland, United States, 20815Clinical Research Institute of Michigan, LLC | Chesterfield Michigan, United States, 48038West Michigan Clinical Research Center | Wyoming Michigan, United States, 49529NY Scientific | Brooklyn New York, United States, 11235Digestive Health Partners - Research Department | Asheville North Carolina, United States, 28801Charlotte Gastroenterolgy & Hepatology | Charlotte North Carolina, United States, 28207Innovo Research:Wilmington Health | Wilmington North Carolina, United States, 28401Optimed Research, LTD | Columbus Ohio, United States, 43235Paramount Medical Research & Consulting, LLC | Middleburg Heights Ohio, United States, 44130Central Sooner Research | Norman Oklahoma, United States, 73071University Gastroenterology | Providence Rhode Island, United States, 02904Gastro One | Cordova Tennessee, United States, 38018Tri-Cities Gastroenterology | Kingsport Tennessee, United States, 37663Clinical Trial Network | Houston Texas, United States, 77074Houston Endoscopy And Research Center, LLC | Houston Texas, United States, 77079Biopharma Informatic, LLC | Houston Texas, United States, 77084Citrine Institute for Research and Wellness | Katy Texas, United States, 77494AngioCardiac Care of Texas, PA | McAllen Texas, United States, 78503Digestive System Healthcare | Pasadena Texas, United States, 77505LinQ Research, LLC | Pearland Texas, United States, 77584Gastroenterology Research of San Antonio | San Antonio Texas, United States, 78229Southern Star Research Institute, LLC | San Antonio Texas, United States, 78229Gastroenterology Associates of Texas - Denise Rodriguez | Sugar Land Texas, United States, 77479Tyler Research Institute, LLC | Tyler Texas, United States, 75701GI Alliance Research Webster | Webster Texas, United States, 77598Care Access Research - Ogden | Ogden Utah, United States, 84403Charlottesville Medical Research | Charlottesville Virginia, United States, 22911Washington Gastroenterology | Bellevue Washington, United States, 98004Washington Gastroenterology dba GI Alliance | Tacoma Washington, United States, 98405Universitair Ziekenhuis Gent - Gastro IBD | Ghent , Belgium, 9000UZ Leuven - E507 Studies IBD tav Tine Hermans | Leuven , Belgium, 3000Vojenska nemocnice Brno, Interni oddeleni | Brno Czech Republic, Czechia, 63600GastroJeka s.r.o | Klatovy Czech Republic, Czechia, 33901FN Ostrava, Interní Klinika | Ostrava Czech Republic, Czechia, 708 52Hepato-gastroenterologie HK, s.r.o. | Hradec Králové Hradec Králové, Czechia, 50012MUDr. Gregar, s.r.o. | Olomouc Olomouc Region, Czechia, 779 00SurGal clinic s.r.o. | Brno , Czechia, 602 00PreventaMed, s.r.o. | Olomouc , Czechia, 779 00Hospices Civils de Lyon - Hôpital Lyon Sud - ARC HGE bâtiment 3I | Lyon - Pierre Benite France, France, 69495CHU Bordeaux - Hôpital Haut-Lévêque | Pessac Gironde, France, 33604CHU Rennes - Hôpital Pontchaillou | Rennes Ille Et Vilaine, France, 35000Centre Hospitalier de Pau | Pau Pyrénées-Atlantiques, France, 64046Chu Besancon | Besançon , France, 25000CHU de LILLE - Bureau des ARCs Gastro - HPDD | Lille , France, 59037Hôpital Saint-Eloi Pôle Digestif ,APEMAD - Recherche clinique | Montpellier , France, 34295CHU Nantes | Nantes , France, 44093Clinique Jules Verne | Nantes , France, 44300Unité de Recherche Clinique (4èmeB) | Nice , France, 06-202Chu de Reims - Hôpital Robert Debré | Reims , France, 51092CHU de Saint-Etienne | Saint-Etienne , France, 42055Chru Nancy Brabois | Vandœuvre-lès-Nancy , France, 54511Praxis Dr. M. Mross - Gastroenterologie | Berlin , Germany, 10118DRK Kliniken Berlin Westend, Gastroenterologie, Studienbüro | Berlin , Germany, 14050Universitätsklinikum Leipzig, Med. Klinik II | Leipzig , Germany, 04 103Bugat Pal Korhaz | Gyöngyös Heves County, Hungary, 3200Clinepert kft | Budapest , Hungary, 1033Semmelweis Egyetem, Belgyógyászati es Hematológiai Klinika | Budapest , Hungary, 1088Pannónia Magánorvosi Centrum | Budapest , Hungary, 1136Clinfan Ltd. Gastroenterology Clinic | Szekszárd , Hungary, 7100Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili) | Brescia , Italy, 25123IRCCS Saverio de Bellis, National Institute of Gastroenterology | Castellana Grotte , Italy, 70013Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico | Milan , Italy, 20122Irccs Ospedale San Raffaele, Gastroenterologia/Ibd Unit, Settore G Piano -1 | Milan , Italy, 20132Fondazione Policlinico Agostino Gemelli IRCCS_ CEMAD | Roma , Italy, 00 168Uoc Gastroenterologia - Policlinico Tor Vergata | Roma , Italy, 00133IRCCS Istituto Clinico Humanitas- Centro Malattie Infiammatorie Intestinali | Rozzano , Italy, 20089A.O.Ordine Mauriziano, SC Gastroenterologia, ambulatorio endoscopia digestiva | Torino , Italy, 10128Solumed Centrum Medyczne | Poznan Greater Poland Voivodeship, Poland, 60-529MZ Badania Słowik Zymła Sp.j. | Knurów Silesian Voivodeship, Poland, 44 190Centrum Medyczne Medyk | Rzeszów Subcarpathian, Poland, 35-326NZOZ Centrum Medyczne KERmed | Bydgoszcz , Poland, 85 231Vitamed Galaj I Cichomski sp.j. | Bydgoszcz , Poland, 85-079Centrum Medyczne Plejady | Krakow , Poland, 30 363KRAKOWSKIE CENTRUM MEDYCZNE Sp. z o.o | Krakow , Poland, 31 501Topolowa Medicenter Ryszawa & Wspólnicy Sp.j. | Krakow , Poland, 31-506IP Clinic | Lodz , Poland, 90-752Med-GASTR SP. Z O.O., SP.K. | Lodz , Poland, 91 034AmiCare Sp. z o.o. Sp. K. | Lodz , Poland, 91 495Bonifraterskie Centrum Medyczne sp. z o.o | Lodz , Poland, 93-357Allmedica Badania Kliniczne Sp. z o.o. Sp. k. | Nowy Targ , Poland, 34-400Twoja Przychodnia Opolskie Centrum Medyczne | Opole , Poland, 45 819Nowe Zdrowie-Ck, Kiełtucki I Wspólnicy Sp. J. | Staszów , Poland, 28 200DC-MED Sp. z o.o. s.k. | Swidnica , Poland, 58 100Twoja Przychodnia - Szczecinskie Centrum Medyczne | Szczecin , Poland, 71-434Sonomed Sp. z o.o. | Szczecin , Poland, 71-685NZOZ FOR MED sp. z o.o. | Wadowice , Poland, 34-100FutureMeds sp. z o. o. | Wroclaw , Poland, 50088PlanetMed Sp.z o.o. | Wroclaw , Poland, 52-210Centrum Medyczne Oporow | Wroclaw , Poland, 52416Centrum Medyczne Kuba Med 2 Sp. z o.o. ETG Zamosc | Zamość , Poland, 22 400Fakultná nemocnica s poliklinikou F. D. Roosevelta Banská Bystrica gastroenterologická ambulancia, II. Interná klinika SZU | Banská Bystrica Slovak Republic, Slovakia, 975 17ALIAN s.r.o. | Bardejov Slovak Republic, Slovakia, 08501CLINIQ, s.r.o | Bratislava Slovak Republic, Slovakia, 81109GASTRO AMBULANCIA, poliklinika Ťahanovce | Košice Slovak Republic, Slovakia, 040 13Fakultna nemocnica Nitra, Interna klinika | Nitra Slovak Republic, Slovakia, 950 01KM Management, spol. s.r.o | Nitra Stare Mesto Slovak Republic, Slovakia, 949 01Accout Center s.r.o. | Šahy Slovak Republic, Slovakia, 93601Fairfield General Hospital | Bury Great Britain, United Kingdom, BL9 7TDClinical Research Unit, Royal Liverpool University Hospital | Waltham Waltham Forest, United Kingdom, E11 1NRKing's College Hospital NHS Foundation Trust | London , United Kingdom, SE5 9RS
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study Documents (Full Text)
Documents provided by Eli Lilly and CompanyStudy Protocol  November 29, 2023Documents provided by Eli Lilly and CompanyStatistical Analysis Plan  November 26, 2024